Abstract:In the past two decades, PET/CT has become an essential modality in oncology increasingly used in the management of gastrointestinal (GI) cancers. Most PET/CT tracers used in clinical practice show some degree of GI uptake. This uptake is quite variable and knowledge of common patterns of biodistribution of various radiotracers is helpful in clinical practice. 18F-Fluoro-Deoxy-Glucose (FDG) is the most commonly used radiotracer and has quite a variable uptake within the bowel. 68Ga-Prostate specific membrane antigen (PSMA) shows intense uptake within the proximal small bowel loops. 11C-methyl-L-methionine (MET) shows high accumulation within the bowels, which makes it difficult to assess bowel or pelvic diseases. One must also be aware of technical artifacts causing difficulties in interpretations, such as high attenuation oral contrast material within the bowel lumen or misregistration artifact due to patient movements. It is imperative to know the common variants and benign diseases that can mimic malignant pathologies. Intense FDG uptake within the esophagus and stomach may be a normal variant or may be associated with benign conditions such as esophagitis, reflux disease, or gastritis. Metformin can cause diffuse intense uptake throughout the bowel loops. Intense physiologic uptake can also be seen within the anal canal. Segmental bowel uptake can be seen in inflammatory bowel disease, radiation, or medication induced enteritis/colitis or infection. Diagnosis of appendicitis or diverticular disease requires CT correlation, as normal appendix or diverticulum can show intense uptake. Certain malignant pathologies are known to have only low FDG uptake, such as early-stage esophageal adenocarcinoma, mucinous tumors, indolent lymphomas, and multicystic mesotheliomas. Response assessment, particularly in the neoadjuvant setting, can be limited by post-treatment inflammatory changes. Post-operative complications such as abscess or fistula formation can also show intense uptake and may obscure underlying malignant pathology. In the absence of clinical suspicion or rising tumor marker, the role of FDG PET/CT in routine surveillance of patients with GI malignancy is not clear.

Advances in the Imaging of Esophageal and Gastroesophageal Junction Malignancies

Imaging in Gastric Cancer: Current Practice and Future Perspectives

Advanced endoscopic imaging for detecting and guiding therapy of early neoplasias of the esophagus

Recent Imaging Updates and Advances in Gynecologic Malignancies

Esophageal cancer: Anatomic particularities, staging, and imaging techniques

Advances in Diagnostic, Staging, and Restaging Evaluation of Esophageal and Gastric Cancer

Image-enhanced endoscopy technology in the gastrointestinal tract: What is available?

Gastric carcinoma: imaging diagnosis, staging and assessment of treatment response

Cross-sectional imaging of gastric cancer: pearls, pitfalls and lessons learned from multidisciplinary conference

Esophageal cancer: patient evaluation and pre-treatment staging

Imaging of Pancreatic Adenocarcinoma: Update on Staging/Resectability

Novel Advances in Qualitative Diagnostic Imaging for Decision Making in Multidisciplinary Treatment for Advanced Esophageal Cancer

Imaging Evaluation of Peritoneal Metastasis: Current and Promising Techniques

Imaging Modalities for Head and Neck Cancer: Present and Future

Added Value of FDG PET/MRI in Gynecologic Oncology: A Pictorial Review

[Advances in radiological studies of gastrointestinal stromal tumors].

Novel approaches to diagnostic imaging of locally advanced cervical cancer

Recent advances in endoscopic management of gastric neoplasms

Value of 18F-FDG PET/MRI in the Preoperative Assessment of Resectable Esophageal Squamous Cell Carcinoma: A Comparison With 18F-FDG PET/CT, MRI, and Contrast-Enhanced CT

Emerging Technologies in Endoscopy for Gastrointestinal Neoplasms: A Comprehensive Overview

Variants and Pitfalls in PET/CT Imaging of Gastrointestinal Cancers